Pipeline
KBP-5074 for CV disease/Hypertension in CKD patients – Initiating global Phase 2b in Q1 2018
KBP-7072 for multiple drug resistant infections – Finish Phase 1 – Ready for global Phase 2
KBP-7026 novel CRTH2 receptor antagonist targeting asthma/COPD – IND Approved & Ready for Phase 1
MANAGEMENT TEAM
• Fred Yang, PhD,CDO
• Michael Miernicki, PhD,VP
• Daniel Wilson, PhD,SVP
• Vince Benn, PhD/MBA,VP
• Jay (Xu-Jie) Zhang, PhD,VP
• Pengfei (Murphy) Guo, PhD,AVP
SCIENTIFIC ADVISORY BOARD
• George Bakris, MD (US)
• John McMurray, MD (UK)
• Bertram Pitt, MD (US)
• Ricard Wunderink, MD (US)
• Faiez Zannad, MD (FR)
KBP BIOSCIENCES SIGNS MEMORANDUM OF UNDERSTANDING WITH BULLFROG AI
KBP Biosciences Co., Ltd. attended the 2017 China BioMed Innovation and Investment Conference.
Careers Information updated on 27 July, 2017
Positive FDA Type B Meeting on KBP-5074
KBP-7072 obtained QIDP and Fast Track Designations
Fred Yang, Ph.D, Chief Development Officer fred.yang@kbpbiosciences.com
116 Village Blvd., Suite 210 Princeton, NJ 08540 Phone: (609) 531-0889(Office) / (267)980-9451(Cell)
